MEDESIS PHARMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 EUR | -2.10% |
|
-10.83% | +61.29% |
| 2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.
The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).
| 1st Jan change | Capi. | |
|---|---|---|
| +61.29% | 6.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALMDP Stock
- News Medesis Pharma S.A.
- Medesis Pharma Wins COVID-19 Drug Trial Approval In Brazil
